Posted: March 2nd, 2010
Council Resolution of 1 March 2010 on the enforcement of intellectual property rights in the internal market
“The Council of the European Union, […] stresses, in the context of the establishment and functioning of the internal market, the importance of using all appropriate means
Posted: March 1st, 2010
Kirin Amgen v. Lithuania, Court of Justice, preliminary question, SPC, opinion A-G Bot, 25 February 2010, Case No. C-66/09
Kirin Amgen applied for an ABC for Aranesp in Lithuania based on its EU Marketing Authorisation (MA) (granted according to Reg. 2309/93) while it did not have a national MA in Lithuania. Article 19a(e) of Regulation 1768/92 stipulates that
Posted: February 25th, 2010
Vanserum Vision AB v. SICK IVP AB, Stockholm District Court, Stockholm , Sweden, 5 February 2010, Cases No. T 1966-07 and T 22033-07 (joint cases)
READ MOREPosted: February 23rd, 2010
Du Pont et al. / Mylan, Losartan SPC, decision in summary proceedings (appeal), Brussels Court of Appeal, 23 February 2010, Case No. A.R. nr. 2010/KR/53
According to the Brussels Court of Appeal, the scope of protection of the SPC for the active ingredient Losartan does not, at first sight (“prima facie”), extend to a generic version of the medicinal product Cozaar Plus® (containing the active ingredients Losartan and HCTZ) under Article 4 of the SPC-Regulation. The main reason raised by the court is that, s
Posted: February 23rd, 2010
Intervet UK Limited v Merial & Others, High Court of Justice, Chancery Division, Patents Court, London, UK, 23 February 2010, Case No. [2010] EWHC 294 (Pat), with thanks to Richard Willoughby, Howrey
Today, the approved judgment of Mr Justice Arnold has been published regarding the UK aspect of a number of associated actions concerning the Defendant’s European patent entitled “Method for the in vitro diagnosis of type II porcine circovirus infection and diagnostic reagents” (the “Patent”). In summary, the Defendants alleged that Intervet had infringed claim 18 of the Patent
Posted: February 22nd, 2010
EPO, Enlarged Board of Appeal, 19 February 2010, Decision No. G 02/08 – Dosage regime/ABBOT RESPIRATORY
The Enlarged Board of Appeal (EBA) answered the questions referred to it in T 1319/04 (OJ EPO 2009, 36) as follows:
Question 1:
Where it is already known to use a medicament to treat an illness
Posted: February 19th, 2010
EPO, Enlarged Board of Appeal, 16 February 2010, Decision No. G 04/08
If an international PCT application has been filed and published in one of the official EPO languages, it is not possible to
Posted: February 18th, 2010
Actavis UK Limited v Novartis AG, High court of Justice, Court of Appeal (Civil Division), London, UK, 17 February 2010, [2010] EWCA Civ 82 The Court of Appeal has dismissed Novartis's appeal against the High Court's decision that its European Patent EP0948320, claiming a sustained release formulation of fluvastatin, a drug used to treat high […]
READ MOREPosted: February 17th, 2010
The EPO Enlarged Board of Appeal handed down its long awaited decision relating to the interpretation of the exclusion for patentability under article 53(c) EPC “method for treatment of the human or animal body by surgery”. Questions were asked to the Enlarged Board in a case about a medical imaging method, whereby a contrast agent was injected into the heart. The referring Board questioned whether this essentially diagnostic method involving a step consisting in a physical intervention was nevertheless excluded from patentability. This question was answered
READ MOREPosted: February 12th, 2010
Du Pont et al. / Mylan, Losartan SPC, decision in summary proceedings (first instance), Pres. Brussels Commercial Court, 12 February 2010, Case No. R.K. 00014/2010
According to the President of the Brussels Commercial Court, the scope of protection of the SPC for the active ingredient Losartan, whose duration had been extended pursuant to Article 36 of the Paediatric Regulation 1901/2006, does not at first sight (“prima facie”) extend to a generic version